Lucid Diagnostics Inc. (LUCD) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
9.84
↑+121% vs avg
5yr avg: 4.45
30Y Low2.1·High7.7
ROE
↓
-2956.4%
↑-216% vs avg
5yr avg: -936.3%
30Y Low-144%·High-136%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LUCD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lucid Diagnostics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $137M | $41M | $59M | $49M | $194M | — | — | — |
| Enterprise Value | $136M | $40M | $55M | $29M | $140M | — | — | — |
| P/E Ratio → | -1.00 | — | — | — | — | — | — | — |
| P/S Ratio | 31.63 | 9.52 | 24.25 | 130.49 | 387.26 | — | — | — |
| P/B Ratio | 9.84 | 7.67 | — | 2.13 | 3.54 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LUCD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.26 | 22.75 | 76.18 | 279.95 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
LUCD Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lucid Diagnostics Inc. earns an operating margin of -1059.6%. Operating margins have expanded from -14899.5% to -1059.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -2956.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -90.2% | -90.2% | -249.2% | -858.6% | -17.0% | — | — | — |
| Operating Margin | -1059.6% | -1059.6% | -1996.8% | -14899.5% | -5483.8% | — | — | — |
| Net Profit Margin | -1047.6% | -1047.6% | -2169.1% | -14899.5% | -5615.6% | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -2956.4% | -2956.4% | -508.0% | -144.4% | -136.2% | — | — | — |
| ROA | -157.0% | -157.0% | -176.2% | -122.8% | -91.8% | -512.9% | -840.7% | -6325.8% |
| ROIC | — | — | — | -2305.2% | — | — | — | — |
| ROCE | -1813.4% | -1813.4% | -441.3% | -142.5% | -133.0% | — | — | — |
LUCD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $22M exceeds total debt of $21M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.94 | 3.94 | — | 0.09 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.20 | — | -0.89 | -0.98 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -0.03 |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -1771.23 | -1771.23 | -116.54 | -7021.38 | -41.61 | — | — | — |
Net cash position: cash ($22M) exceeds total debt ($21M)
LUCD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.07x means Lucid Diagnostics Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.89x to 1.07x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.07 | 1.07 | 0.75 | 2.89 | 13.45 | 0.09 | 0.06 | 0.02 |
| Quick Ratio | 1.05 | 1.05 | 0.74 | 2.88 | 13.34 | 0.04 | 0.06 | 0.02 |
| Cash Ratio | 0.95 | 0.95 | 0.64 | 2.67 | 12.60 | 0.01 | 0.02 | 0.02 |
| Asset Turnover | — | 0.14 | 0.09 | 0.01 | 0.01 | — | — | — |
| Inventory Turnover | 24.24 | 24.24 | 30.50 | 32.56 | 1.19 | — | — | — |
| Days Sales Outstanding | — | 34.01 | 6.76 | 16.46 | 146.00 | — | — | — |
LUCD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lucid Diagnostics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $51M | $42M | $36M | $36M | $37M | $37M | $37M |
Peer Comparison
Compare LUCD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LUCDYou | $137M | -1.0 | — | — | -90.2% | -1059.6% | -2956.4% | — | — |
 GKOS | $8B | -40.9 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 NNOX | $115M | -1.9 | — | — | -94.0% | -502.9% | -27.8% | -27.9% | — |
 CDXS | $234M | -5.2 | — | — | 79.5% | -54.5% | -74.9% | -31.9% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NTRA | $31B | -144.6 | — | 285.5 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 GUTS | $115M | -0.4 | — | — | — | — | -744.2% | -1115.0% | — |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 EW | $48B | 45.2 | 25.4 | 35.7 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See LUCD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LUCD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LUCD vs GKOS
Side-by-side business, growth, and profitability comparison vs Glaukos Corporation.
Start ComparisonLUCD — Frequently Asked Questions
Quick answers to the most common questions about buying LUCD stock.
What is Lucid Diagnostics Inc.'s P/E ratio?
Lucid Diagnostics Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
What is Lucid Diagnostics Inc.'s ROE?
Lucid Diagnostics Inc.'s return on equity (ROE) is -2956.4%. The historical average is -140.3%.
Is LUCD stock overvalued?
Based on historical data, Lucid Diagnostics Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Lucid Diagnostics Inc.'s profit margins?
Lucid Diagnostics Inc. has -90.2% gross margin and -1059.6% operating margin.